Company Filing History:
Years Active: 2021-2022
Title: Joachim Koch - Innovator in Immunotherapy
Introduction
Joachim Koch is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of immunotherapy, particularly through his innovative approaches to natural killer (NK) cell engagement.
Latest Patents
Koch holds 2 patents that focus on enhancing NK cell-based immunotherapy. His latest patents include a combination of an anti-CD16A antibody with a cytokine. This invention relates to an anti-CD16A antigen binding protein designed for intermittent administration alongside a cytokine. In certain embodiments, the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody. Another notable patent involves NK cell engaging antibody fusion constructs. This invention pertains to multispecific antigen-binding proteins that engage NK cells to trigger cytotoxicity by interacting with CD16A expressed on NK cells. The antigen-binding protein comprises at least two CD16A antigen-binding moieties and an additional target antigen-binding moiety.
Career Highlights
Joachim Koch is associated with Affimed GmbH, a company known for its innovative approaches in immunotherapy. His work has been pivotal in advancing the understanding and application of NK cell engagement in therapeutic settings.
Collaborations
Koch collaborates with notable colleagues, including Martin Treder and Uwe Reusch, who contribute to his research and development efforts.
Conclusion
Joachim Koch's contributions to immunotherapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in cancer treatment and immunological research.